-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Guangxiang Pharmaceutical and Guolong Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Have Been Recognized as Model Specialized, Sophisticated, and Novel Enterprises in Hebei Province.
Category:
TIME：2022-01-22
【SUMMARY】
Recently, the Hebei Provincial Department of Industry and Information Technology announced the fourth batch of Hebei Province’s “Specialized, Refined, Distinctive, and Innovative” demonstration enterprises, with Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd. both recognized as such.
At the start of the new year, good news has been coming in one after another. Recently, the Hebei Provincial Department of Industry and Information Technology announced the fourth batch of Hebei Province’s “Specialized, Refined, Distinctive, and Innovative” demonstration enterprises, and Shijiazhuang Sihua Pharmaceutical Group’s Hebei Guangxiang Pharmaceutical Co., Ltd. and Hebei Guolong Pharmaceutical Co., Ltd. were both recognized as Hebei Province’s specialized, refined, distinctive, and innovative demonstration enterprises.
According to reports, “specialized, refined, distinctive, and innovative” demonstration enterprises are those that embody the characteristics of specialization, refinement, distinctiveness, and innovation. They are required to rank among the top players in their respective niche markets in terms of economic performance, degree of specialization, innovation capability, and business management, serving as exemplars of cutting-edge innovation capacity and mastery of core technologies in key areas within their industries. This award conducts a comprehensive, multi-dimensional assessment and rigorous professional review of enterprises based on a wide range of indicators, including operational metrics, R&D investment, innovation capacity, market share, and intellectual property rights.
Guangxiang Pharmaceutical Group is a large-scale domestic API industrialization base that leverages bulk APIs such as caffeine, metronidazole, theophylline, aminophylline, and nifedipine as its core while also engaging in the production, R&D, and export of dozens of high-value-added specialty APIs, including arbidol, pentoxifylline, argatroban, rosuvastatin calcium, and pitavastatin calcium. The company’s market influence continues to grow. Guangxiang Pharmaceutical has established research and innovation platforms for anti-infective, psychotropic, respiratory, and diabetes-related APIs, and has collaborated with leading research institutions such as Tsinghua University and Tianjin University. These partnerships have helped forge an independent innovation system centered on industry–university–research–application linkages and focused on building technological platforms and developing new products, thereby providing a solid foundation for product innovation and development. The company regards intelligent manufacturing and digitalization as key enablers for enhancing production efficiency and product quality, continuously introducing advanced international technologies and smart, digitally integrated equipment. As a pioneer in the industry, Guangxiang Pharmaceutical has embarked on a new path of digital transformation and upgrading in manufacturing, while benchmarking against international best practices. It has also been the first in the sector to adopt cutting-edge, cross-cutting technologies—such as high-temperature wet oxidation for COD reduction, MVR desalination, ozone-catalyzed oxidation, and biochemical treatment—to address critical, industry-wide challenges, thus driving corporate growth and advancing technological progress across the industry. The company has been recognized as a High-Tech Enterprise, Hebei Provincial Enterprise Technology Center, Hebei Provincial Technology Innovation Center, Hebei Provincial Engineering Research Center for Micro-Reactor Continuous Synthesis of APIs, Postdoctoral Research Station, Hebei Provincial Science-and-Technology-Based SME, Hebei Provincial Specialized, Sophisticated, and Novel SME, Hebei Provincial Industrial Enterprise R&D Institution (Level A), and Hebei Provincial Green Factory.
Guolong Pharmaceutical Group has translated its innovative development philosophy into strategic initiatives, continuously deepening supply-side structural reform and optimizing its production–sales mix. Leveraging technological innovation, product innovation, and business-model innovation—coupled with state-of-the-art equipment, cutting-edge technologies, and world-class management—the company has embarked on a path of innovative, green, and high-quality development. Guided by the principle of high-quality development, the Group has integrated its own strengths with those of research institutes and other institutions to tackle key technological challenges, resolve critical issues in manufacturing processes, break through technical bottlenecks hindering industry growth, and steadily enhance its independent R&D capabilities and the dissemination of scientific and technological achievements. As a result, the company has achieved refined, standardized, and scientifically driven operations. Its meticulously developed, portfolio-based, and high-end API products have garnered widespread attention and recognition from both the industry and society; flagship products such as azithromycin, hydroxyethyl starch 40, and hydroxyethyl starch 130/0.4 consistently rank among the top sellers in the domestic market. The company has successively been recognized as a High-Tech Enterprise, an A-Level R&D Institution for Industrial Enterprises in Hebei Province, a Science-and-Technology-Based SME in Hebei Province, a Specialized, Sophisticated, and Novel SME in Hebei Province, and a Model Enterprise for Technological Innovation in Hebei Province.
A relevant executive of the Group stated that the company will continue to deepen its expertise in the specialty API sector, leveraging the national policies that increasingly strengthen the cultivation, support, and demonstration-led development of specialized, refined, distinctive, and innovative enterprises. Upholding an innovation-driven approach to change and steadfastly pursuing a “specialized, refined, distinctive, and innovative” development path, the Group aims to better harness its role as a model and leader in driving industry-wide progress.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
